Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87


Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.

Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ.

Nat Med. 2011 Aug 7;17(9):1116-20. doi: 10.1038/nm.2402.


Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Cancer Res. 2013 Jul 1;73(13):4075-85. doi: 10.1158/0008-5472.CAN-12-4579. Epub 2013 Apr 30.


Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL.

Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14372-7. doi: 10.1073/pnas.1303204110. Epub 2013 Aug 12.


Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation.

Adams JR, Xu K, Liu JC, Agamez NM, Loch AJ, Wong RG, Wang W, Wright KL, Lane TF, Zacksenhaus E, Egan SE.

Cancer Res. 2011 Apr 1;71(7):2706-17. doi: 10.1158/0008-5472.CAN-10-0738. Epub 2011 Feb 15.


Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations.

Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M, Haverty PM, Fedorowicz G, Heldens S, Soriano RH, Zhang Z, Wallin JJ, Johnson L, Merchant M, Modrusan Z, Stern HM, Seshagiri S.

Oncogene. 2013 Jan 17;32(3):318-26. doi: 10.1038/onc.2012.53. Epub 2012 Feb 27.


Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.

Meyer DS, Brinkhaus H, Müller U, Müller M, Cardiff RD, Bentires-Alj M.

Cancer Res. 2011 Jul 1;71(13):4344-51. doi: 10.1158/0008-5472.CAN-10-3827. Epub 2011 Apr 11.


Initiating breast cancer by PIK3CA mutation.

Miller TW.

Breast Cancer Res. 2012 Feb 7;14(1):301.


Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.

Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA.

PLoS One. 2012;7(5):e36924. doi: 10.1371/journal.pone.0036924. Epub 2012 May 30.


Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors.

Koren S, Bentires-Alj M.

FEBS J. 2013 Jun;280(12):2758-65. doi: 10.1111/febs.12175. Epub 2013 Mar 1. Review.


Mutations in PIK3CA are infrequent in neuroblastoma.

Dam V, Morgan BT, Mazanek P, Hogarty MD.

BMC Cancer. 2006 Jul 5;6:177.


Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors.

Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D, Xing M.

J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93. Epub 2005 May 31.


Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.

Cufí S, Corominas-Faja B, Lopez-Bonet E, Bonavia R, Pernas S, López IÁ, Dorca J, Martínez S, López NB, Fernández SD, Cuyàs E, Visa J, Rodríguez-Gallego E, Quirantes-Piné R, Segura-Carretero A, Joven J, Martin-Castillo B, Menendez JA.

Oncotarget. 2013 Sep;4(9):1484-95.


E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.

Ladu S, Calvisi DF, Conner EA, Farina M, Factor VM, Thorgeirsson SS.

Gastroenterology. 2008 Oct;135(4):1322-32. doi: 10.1053/j.gastro.2008.07.012. Epub 2008 Jul 17.


Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.

Jang JW, Boxer RB, Chodosh LA.

Mol Cell Biol. 2006 Nov;26(21):8109-21. Epub 2006 Aug 14.


PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.

Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R.

Cancer Res. 2013 Jan 1;73(1):276-84. doi: 10.1158/0008-5472.CAN-12-1726. Epub 2012 Oct 12.


Common and distinct features of mammary tumors driven by Pten-deletion or activating Pik3ca mutation.

Liu JC, Wang DY, Egan SE, Zacksenhaus E.

Oncotarget. 2016 Feb 23;7(8):9060-8. doi: 10.18632/oncotarget.6985.


PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.

Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K, Inazawa J.

Cancer Sci. 2006 Dec;97(12):1351-8.


PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis.

Ilic N, Utermark T, Widlund HR, Roberts TM.

Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E699-708. doi: 10.1073/pnas.1108237108. Epub 2011 Aug 29.


Oncogenic PI3K and its role in cancer.

Samuels Y, Ericson K.

Curr Opin Oncol. 2006 Jan;18(1):77-82. Review.


PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.

Green S, Trejo CL, McMahon M.

Cancer Res. 2015 Dec 15;75(24):5378-91. doi: 10.1158/0008-5472.CAN-15-1249. Epub 2015 Nov 13.

Supplemental Content

Support Center